Colorectal cancer is the 3rd most common cancer and one of the leading causes of death among cancer types. For patients whose cancer metastasized , the treatment options are chemotherapy, typically FOLFOX or FOLFIRI, and/or targeted therapy.
The mTOR oncogenic pathways (PI3K/AKT/mTOR) are frequently dysregulated in human cancers, including colorectal cancer [1]. Clinical studies demonstrated improved efficacy of mTOR inhibitors combined with the standard of care, in particular in patients with PTEN deficiency. [2]
AADi is conducting a study to evaluate the optimal dose and utility of ABI-009 combined with a standard of care, FOLXOX + bevacizumab, as first-line treatment in patients with metastatic colorectal cancer with and without PTEN deficiency (NCT03439462).
Laes et al. Oncotarget 2017 8(48): 84426-84433.
Gilcrease et al. Invest New Drug 2018 ahead of print.
